FLGT Q3 2024 Earnings — Fulgent Genetics, Inc. Revenue & Financial Results | Market Cap Arena

FLGTFulgent Genetics, Inc.

$458M

Q3 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$72M-15.3% YoY

Gross Profit

$27M37.3% margin

Operating Income

-$17M-23.8% margin

Net Income

-$15M-20.4% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+1.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$35M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$99M

Stockholders' Equity

$1.1B

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$85M	-15.3%
Gross Profit	$27M	$40M	-32.8%
Operating Income	-$17M	$214,000	-8080.8%
Net Income	-$15M	-$13M	-11.8%

Revenue Segments

Laboratory Services

$72M100%

Geographic Segments

UNITED STATES

$66M84%

Non-US

$6M8%

Other Countries

$3M4%

CHINA

$3M4%